2014
Epigenetic regulation of OPA1 sensitizes hepatocellular carcinoma to sorafenib‐induced apoptosis (59.1)
Puszyk W, Dong H, Zhao F, Shisgal P, Cabrera R, Neslon D, Liu C. Epigenetic regulation of OPA1 sensitizes hepatocellular carcinoma to sorafenib‐induced apoptosis (59.1). The FASEB Journal 2014, 28 DOI: 10.1096/fasebj.28.1_supplement.59.1.Peer-Reviewed Original ResearchDNA methylationHepatocellular carcinomaEpigenetic regulationProtein OPA1HCC cellsMitochondrial fragmentationGene promoterC releaseEpigenetic analysisXenograft tumor growthEpigenetic markersSorafenib-induced apoptosisAkt pathwayOPA1HCC xenograft tumor growthHepatocellular carcinoma cellsNovel therapeutic targetExpression levelsTumorigenesis of HCCIdentification of patientsPathogenesis of HCCOPA1 knockdownApoptosisPrimary hepatocytesSensitivity of HCC
2012
OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma
Zhao X, Tian C, Puszyk W, Ogunwobi O, Cao M, Wang T, Cabrera R, Nelson D, Liu C. OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma. Laboratory Investigation 2012, 93: 8-19. PMID: 23108376, PMCID: PMC3860369, DOI: 10.1038/labinvest.2012.144.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisCarcinoma, HepatocellularCell Line, TumorCytochromes cDown-RegulationGene Knockdown TechniquesGTP PhosphohydrolasesHumansLiverLiver NeoplasmsMiceMice, SCIDMitochondriaNiacinamidePhenylurea CompoundsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRaf KinasesRas ProteinsRNA, Small InterferingSignal TransductionSorafenibXenograft Model Antitumor AssaysConceptsHepatocellular carcinomaSorafenib-induced apoptosisHCC xenograft tumor growthOptic atrophy 1HCC cellsPatients' hepatocellular carcinomaNon-tumor tissue samplesAdvanced hepatocellular carcinomaPathogenesis of HCCNovel therapeutic targetTumorigenesis of HCCXenograft tumor growthTumor tissue analysisNormal human primary hepatocytesHuman primary hepatocytesCell growth inhibitionSorafenib treatmentHCC patientsTherapeutic targetExposure of cellsTumor growthMitochondrial injuryPatientsSorafenibOPA1 expressionGlypican‐3 as a Potential Therapeutic Target for Hepatocellular Carcinoma Immunotherapy
Trinh T, Liu C. Glypican‐3 as a Potential Therapeutic Target for Hepatocellular Carcinoma Immunotherapy. The FASEB Journal 2012, 26: 405.1-405.1. DOI: 10.1096/fasebj.26.1_supplement.405.1.Peer-Reviewed Original ResearchHCC cell linesDifferent HCC cell linesGlypican-3Hepatocellular carcinomaTherapeutic targetCell linesNon-tumor liver tissuesHepatocellular Carcinoma ImmunotherapyCell proliferationNovel therapeutic targetPotential therapeutic targetCancer cell proliferationInhibited cell proliferationDose-dependent mannerAnti-GPC3 antibodiesHuman HCC tissuesNormal primary hepatocytesHCC immunotherapyCell surface heparinGPC3 expressionHCC tissuesLiver tissueImmunotherapyWestern blotHuman tumors
2010
Influence of Serum and Soluble CD25 (sCD25) on Regulatory and Effector T‐cell Function in Hepatocellular Carcinoma
Cabrera R, Ararat M, Eksioglu E, Cao M, Xu Y, Wasserfall C, Atkinson M, Liu C, Nelson D. Influence of Serum and Soluble CD25 (sCD25) on Regulatory and Effector T‐cell Function in Hepatocellular Carcinoma. Scandinavian Journal Of Immunology 2010, 72: 293-301. PMID: 20883314, PMCID: PMC2951624, DOI: 10.1111/j.1365-3083.2010.02427.x.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaHCC serumSerum-free mediumSoluble CD25Pg/Effector T cell responsesEffector T cell functionSerum-mediated suppressionRegulatory T cellsT cell responsesSera of patientsT cell functionHealthy control cellsNovel therapeutic targetDose-dependent fashionCD25 cell surface expressionTeff responsesTreg suppressionInfluence of serumCirrhosis patientsTeff proliferationTumor burdenCD25 expressionCell surface expressionPoor survival